. 2015 Jan 4;204(1):57–68. doi: 10.1007/s00430-014-0374-x

Table 2.

Rates of vaccine-induced anti-HBs seropositivity for the three groups after eight i.m. injections of 20 μg/dose Sci-B-Vac™ as tested at month 18, 10, months after administration of the last treatment. VAC-recipients of Sci-B-Vac™, V + L-recipients of Sci-B-Vac™ and Lamivudine, LAM recipients of lamivudine. Reproduced by permission from Ref. [81]

Mo	No. (%) of anti-HBs responders in the following treatment group			P ^a
Mo	VAC	V + L	LAM	P ^a
3	2 (3.3)	3 (5.0)	0	NS
9	13 (21.7)	21 (35.0)	0	<0.001
12	17 (28.3)^b	27 (45.0)^b	0	<0.001
15	17 (28.3)^b	28 (46.7)^b	0	<0.001
18	19 (31.7)^b	31 (51.7)^b	0	<0.001

^aFor the overall treatment effect

^bThe difference between the VAC and V + L groups was significant (P < 0.05)